Lysophosphatidic Acid-Mediated Inflammation at the Heart of Heart Failure

AbstractPurpose of ReviewThe primary aim of this review is to provide an in-depth examination of the role bioactive lipids —namely lysophosphatidic acid (LPA) and ceramides—play in inflammation-mediated cardiac remodeling during heart failure. With the global prevalence of heart failure on the rise, it is critical to understand the underlying molecular mechanisms contributing to its pathogenesis. Traditional studies have emphasized factors such as oxidative stress and neurohormonal activation, but emerging research has shed light on bioactive lipids as central mediators in heart failure pathology. By elucidating these intricacies, this review aims to:Bridge the gap between basic research and clinical practice by highlighting clinically relevant pathways contributing to the pathogenesis and prognosis of heart failure.Provide a foundation for the development of targeted therapies that could mitigate the effects of LPA and ceramides on heart failure.Serve as a comprehensive resource for clinicians and researchers interested in the molecular biology of heart failure, aiding in better diagnostic and therapeutic decisions.Recent FindingsRecent findings have shed light on the central role of bioactive lipids, specifically lysophosphatidic acid (LPA) and ceramides, in heart failure pathology. Traditional studies have emphasized factors such as hypoxia-mediated cardiomyocyte loss and neurohormonal activation in the development of heart failure. Emerging research has elucidated the...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research